Boston Scientific Files 8-K: Other Events & Financials

Ticker: BSX · Form: 8-K · Filed: Jan 16, 2025 · CIK: 885725

Boston Scientific CORP 8-K Filing Summary
FieldDetail
CompanyBoston Scientific CORP (BSX)
Form Type8-K
Filed DateJan 16, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: BSX

TL;DR

BSX filed an 8-K on Jan 16, 2025, covering 'Other Events' and financial exhibits.

AI Summary

On January 16, 2025, Boston Scientific Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations. Specific details regarding new events or financial figures are not elaborated in the provided text, but the filing serves as a formal notification to the SEC.

Why It Matters

This 8-K filing by Boston Scientific Corporation signals important updates or disclosures to investors and the market regarding the company's financial statements and other significant events.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not appear to contain immediate negative news or significant financial distress.

Key Players & Entities

FAQ

What specific "Other Events" are being reported by Boston Scientific Corporation in this 8-K filing?

The provided text does not specify the details of the 'Other Events'; it only indicates that this item is part of the filing.

What is the significance of the "Financial Statements and Exhibits" section in this filing?

This section indicates that updated or relevant financial statements and supporting exhibits are being provided to the SEC as part of the 8-K report.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on January 16, 2025.

Where is Boston Scientific Corporation incorporated?

Boston Scientific Corporation is incorporated in Delaware.

What is the business address of Boston Scientific Corporation?

The business address is 300 Boston Scientific Way, Marlborough, Massachusetts, 01752-1234.

Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-01-16 16:26:10

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 8, 2025, the United States District Court for the District of Massachusetts (the "Court") issued an order (the "Preliminary Approval Order") granting preliminary approval to a proposed settlement of two shareholder derivative actions and demands for access to certain books and records of Boston Scientific Corporation (the "Company"), which actions were related to the prior recall and retirement of the LOTUS Edge Aortic Valve System, as previously disclosed by the Company. The proposed settlement was entered into, subject to the Court's approval, through a stipulation and agreement of settlement, dated September 6, 2024 (the "Stipulation of Settlement"), by and among plaintiff Diane Nachbaur, plaintiff Frank Tripson, Excavators Union Local 731 Pension Fund, the Company as a nominal defendant, and the individual named defendants therein. The Court has scheduled a hearing on March 25, 2025, at 2:00 p.m. Eastern Time, to determine whether it should issue an order for final approval of the proposed settlement. As required by the Preliminary Approval Order, the Company is filing the Stipulation of Settlement, with exhibits thereto, and the Notice of Proposed Derivative Settlement with this Current Report on Form 8-K, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Stipulation and Agreement of Settlement, dated September 6, 2024 99.2 No tice of Proposed Derivative Settlement, dated January 8, 2025 104 Cover Page Interactive Date File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 16, 2025 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing